Eli Lilly’s obesity drug Zepbound has shown positive results in treating obstructive sleep apnea, positioning it as a potential first approved treatment for the disorder. In a year-long Phase 3 study, patients with obesity not on PAP therapy experienced a significant reduction in breathing interruptions during sleep while taking Zepbound compared to those on a placebo. This development gives Zepbound an advantage in the competitive obesity market and opens up new possibilities for addressing obstructive sleep apnea. Eli Lilly’s findings were announced in a press release, showcasing the drug’s effectiveness in improving sleep quality for patients with obesity and OSA.
Source link
Zepbound effective in obstructive sleep apnea trials
